Endo International plc 2015 Annual Report
Endo international plc 2015 annual report
endo international plc
2015 annual report

Company Information

Directors

Roger H. Kimmel 1, 3, 4, 5
Chairman of the Board
Vice Chairman, Rothschild Inc.

Rajiv De Silva
President and Chief Executive Officer

Shane M. Cooke 1, 4
President, Alkermes

Arthur J. Higgins 2, 4, 5
Senior Advisor, Blackstone Healthcare Partners

Nancy J. Hutson Ph.D.3, 4, 5
Retired Senior Vice President, Pfizer Global Research and Development

Michael Hyatt 2, 3, 4
Senior Advisor, Irving Place Capital

William P. Montague 1, 2, 3, 4
Retired Chief Executive Officer and Director,
Mark IV Industries, Inc.

Jill D. Smith 1, 3, 5
Former Chairman, Chief Executive Officer and President, DigitalGlobe Inc.

William F. Spengler 1, 2, 5
Former President,
ChromaDex Corporation

  1. Audit Committee Member
  2. Compensation Committee Member
  3. Nominating & Governance Committee Member
  4. Transactions Committee Member
  5. Operations Committee Member

Executive Officers*

Rajiv De Silva
President and Chief Executive Officer

Paul V. Campanelli
President, Par Pharmaceutical

Susan T. Hall, Ph.D.
Executive Vice President, Chief Scientific Officer, Global Head of Research and Development and Quality

Brian Lortie
President, U.S. Branded Pharmaceuticals

Matthew J. Maletta
Executive Vice President and Chief Legal Officer

Daniel A. Rudio
Vice President, Controller and Chief Accounting Officer

Suketu (Suky) P. Upadhyay
Executive Vice President and Chief Financial Officer

Hemanth J. Varghese, Ph.D.
President, International Pharmaceuticals and Executive Vice President of Corporate Development
(effective March 2016)

* Section 16(b) Executive Officers

Senior Leadership

Lawrence A. Cunningham
Executive Vice President, Human Resources

Robert J. Cobuzzi Jr., Ph.D.
President, Endo Ventures Limited

Keri P. Mattox
Senior Vice President, Investor Relations and Corporate Affairs

Jon A. Smollen
Executive Vice President and
Chief Compliance Officer

Julie B. Yankovich
Senior Vice President, Employee Communications and Business Operations

Company Secretary

Orla Dunlea
International Legal Counsel and Company Secretary

Company Information

Auditors

PricewaterhouseCoopers LLP
Two Commerce Square,
Suite 1700
2001 Market Street
Philadelphia, PA 19103-7045

Corporate Counsel

A&L Goodbody
IFSC
North Wall Quay
Dublin 1
Ireland

Skadden, Arps, Slate, Meagher & Flom LLP
4 Times Square
New York, NY 10036

Transfer Agent

Computershare
P.O. Box 43001
Providence, RI 02940

250 Royall Street
Canton, MA 02021

Investor Relations

Keri P. Mattox
Senior Vice President,
Investor Relations and Corporate Affairs
+1 484 216 7912

Annual Shareholder Meeting

Thursday, June 9, 2016
at 8:00 a.m.
Irish Standard Time (IST)

First Floor
Minerva House
Simmonscourt Road
Ballsbridge
Dublin 4
Ireland

Stock Exchange

Endo common stock is listed on the NASDAQ Global Select Market under the ticker symbol ENDP and on the Toronto Stock Exchange (TSX) under the ticker symbol ENL. Note: NASDAQ quotes are in USD$ and TSX quotes are in CAD$.

SEC Form 10-K

A copy of the company's annual report on Form 10-K, as filed with the U.S. Securities and Exchange Commission (SEC), is available on our website (www.endo.com) or may be obtained without charge by writing to:

First Floor
Minerva House
Simmonscourt Road
Ballsbridge
Dublin 4
Ireland

Caution: Forward-looking Statements

This document contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from these expectations due to changes in economic, business, competitive, market and regulatory factors. More information about those factors is contained in Endo's filings with the U.S. Securities and Exchange Commission.

ASPEN, ASTORA WOMEN’S HEALTH, AUXILIUM, BELBUCA, ENDO, AVEED, SUPPRELIN, NASCOBAL, LITHA, OPANA ER, PALADIN, PALADIN LABS, PAR, PAR PHARMACEUTICAL, QUALITEST, SOMAR, and XIAFLEX are trademarks or registered trademarks of Endo Pharmaceuticals Inc. or its affiliates in the United States and certain international markets. AMS MEN’S HEALTH is a trademark of Boston Scientific Scimed, Inc. SEROQUEL is a registered trademark of AstraZeneca UK Limited LLC. VOLTAREN is a registered trademark of Novartis AG Corporation. ICLUSIG is a registered trademark of ARIAD Pharmaceuticals, Inc. ZETIA is a registered trademark of MSD International GMBH LLC. The registration symbol ® indicates that the particular trademark is registered with the United States Patent and Trademark Office.

Shaping the future

At Endo, we are committed to improving lives while creating value. Toward this goal, we seek to manage our Company for the future in order to create continued, sustainable growth. Our 2015 Digital Annual Report uses the metaphor of origami, the art of transforming a simple piece of paper into magnificent shapes, to illustrate this cycle of growth and the evolution of our core businesses: U.S. Branded, U.S. Generic and International Pharmaceuticals. We believe that our Key Values—leadership, teamwork, innovation, being results-driven and having a sharp customer focus—are what drives us to success in not only managing for the future, but also actively shaping it on behalf of our customers and shareholders.